NGM Bio reports positive Phase 2 data for Aldafermin
NGM Biopharmaceuticals Inc. (NGM) reported final data from its 24-week Phase 2 study of aldafermin 1 mg. The trial involved patients with non-alcoholic steatohepatitis. The readout included a new analysis of data gathered from Cohort 4 consisting of NASH patients with stage 3 liver fibrosis. The company also reported that it has completed enrolment for its ongoing Phase 2b ALPINE 2/3 study.
The data from Phase 2 trial of aldafermin 1 mg showed that the drug candidate had a potent anti-fibrotic impact on NASH